InSitu Biologics is pleased to announce that it has entered into an agreement with the Mayo Clinic to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.

For more details regarding this announcement, please take some time to read the below press release.

InSitu Biologics Welcomes Dr. M. Yaman to Medical Advisory Board